Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patritumab Deruxtecan in Advanced Gastrointestinal Cancers
MOH_2024-07-24_013550Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of patritumab deruxtecan in colorectal cancer (CRC), biliary cancer and hepatocellular carcinoma (HCC) (3 cohorts), sponsored by Merck & Co. Started Jul 2024; status: recruiting.
02
Drugs
patritumab deruxtecan
03
Conditions
colorectal cancer (CRC)biliary cancerhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on MOH_2024-07-24_013550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-07-24_013550.